All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On 5 April 2019, Philippe Armand from Dana-Farber Cancer Institute, Boston, MA, USA, and colleagues, published in Blood results from a phase II clinical trial (NCT02362997) that investigated the potential benefit of pembrolizumab treatment following autologous stem cell transplantation (ASCT) in patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL).
Pembrolizumab is a humanized IgG4 anti-programmed cell death-1 (PD-1) antibody. Since cHL is vulnerable to PD-1 blockade, the investigators sought to assess whether pembrolizumab is an efficient post-ASCT consolidation therapy for patients with R/R cHL. The primary endpoint of the study was the hypothesis that progression-free survival (PFS) at 18 months after ASCT would improve with pembrolizumab from 60% to 80%. Secondary endpoints included safety, response rates, and overall survival at 18 months post-ASCT.
Pembrolizumab as consolidation treatment after ASCT had an acceptable safety profile, and resulted in high PFS in patients with R/R cHL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox